Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

The Institute of Cancer Research

Headquarters: London, United Kingdom
Year Founded: 1909
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Aug 2, 2024
Distillery Therapeutics

Inhibiting NBS1 lactylation for chemotherapy resistance

BioCentury | Aug 1, 2024
Distillery Therapeutics

RIPK1 PROTAC for cancer

BioCentury | Oct 20, 2023
Discovery & Translation

Targeted protein degrader design insights; plus Long COVID, obesity and more

BioCentury’s roundup of translational innovations
BioCentury | Jun 7, 2022
Distillery Therapeutics

Targeting USP25 for pancreatic cancer

BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Versant-built start-up finds targets, compounds for protein degradation via structural biology and proteomics
BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

BioCentury’s roundup of preclinical news
BioCentury | Oct 16, 2019
Company News

AI play Healx raises $56M to repurpose drugs for rare disease

How Healx is tackling rare diseases using AI and input from patient groups
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

Solutions to cancer drug resistance could come from new understanding about tumor evolution and advances in liquid biopsies.
Items per page:
1 - 10 of 130